Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Altoprev lovastatin XL regulatory update

FDA approved several label changes for the statin class of cholesterol drugs, including eliminating the need for routine periodic monitoring of liver enzymes. The labels now recommend that liver enzyme tests should be performed before starting statin therapy and as clinically indicated thereafter. The agency concluded that serious liver

Read the full 496 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE